Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
NCT00875433
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
BIBW 2992
Sponsor
Boehringer Ingelheim